FBXL19 and acute myeloid leukemia: ROC curve analysis of healthy controls and pediatric AML patients revealed that serum levels of FBXL19‐AS1 was able to distinguish AML patients from healthy controls and therefore FBXL19‐AS1 is a potential diagnostic marker for AML patients.